03/05/2026
When the standard path hasn’t led to relief, it’s easy to feel stuck. But “treatment resistant” doesn’t mean “untreatable.”
Spravato® (esketamine) is a breakthrough nasal spray designed for adults who haven’t found success with traditional antidepressants.
The Impact:
In the TRD-TRANSFORM-2 study, over 50% of patients achieved remission from treatment resistant depression, with many maintaining a strong response over time.
Do you qualify?
You may be a candidate if you’ve been diagnosed with Major Depressive Disorder and have tried two or more oral antidepressants without meaningful improvement. There are additional clinical factors that may make you eligible, and the best way to determine that is through a personalized consultation.
Ready to see if Spravato could be the missing piece in your wellness journey? DM us or click the link in our bio to schedule your consultation. 🩺